In times of technological transition, scientific innovations need the nourishment of commercial exposure to thrive and survive. This is true in both life sciences and AI. Embedding AI into our business processes takes time, but that window gets ever more compressed as competitive forces demand effective implementation. Our strategy is to establish generative AI upskilling with a particular focus on MI specialists.
AIMI - an AI platform for pharmaceutical specialists in medicines information
AIMI brings AI capabilities to the medical information function by offering an AI-driven platform specifically designed for professionals in MI. Our solution empowers your team by leveraging tailor-made knowledge bases, ensuring that the insights you receive are not just data-driven but strategically aligned with your unique requirements.
AIMI has been developed as an assistant to address medicine information enquiries . The critical issue is to ensure that responses are reliable and their source easily identified. Whether in a busy medicines information pharmacy or a medical information function in a pharmaceutical we wanted to explore how generative AI can provide efficient answers to, often complex, problems.
Adverse drug reaction analysis from reports from the FDA Adverse Event Reporting System (FAERS)
ADRx from PharmAdvisor is a unique online resource that aids healthcare professionals in accurately screening for and diagnosing adverse drug reactions.
This is accomplished this by evaluating a patient's symptoms and signs with the world's largest, publically available, voluntary reporting databases: the Food and Drug Administration's Adverse Event Reporting System (FAERS).
Results are displayed in clear tables. By using the PRR statistic, users can easily identify which drugs have a higher rate of reporting for specific side effects.
Faster diagnosis: by using ADRx, clinicians can improve the time to diagnosis and reduce the number of repeat visits necessary for patients
Personalised care: ADRx is particularly useful for patients, such as the elderly, who often have multiple conditions and take multiple medicines
Reduced Risk: by comparing side effects across differents medicines, ADRx helps clinicians make more informed decisions, thereby reducing the potential for side effects.
Improved diagnostic throughput: ADRx can speed up the diagnostic process by offering immediate information about potential side effects. This enables clinicians to identify the causes of a patient's symptoms, allowing them to see more patients.
Reduced repeat visits: By aiding accurate and quick diagnoses, ADRx can minimize the need for patients to return for follow-up visits related to unresolved or misdiagnosed issues. This improves patient satisfaction and frees up clinician time for other tasks or patients.
Improved medication response: ADRx extends the number of observed ADRs by a factor of 10 over those listed in datasheets. The analysis of this broader range of ADRs can provide prescribers with more choices of medicines.
Recent research* indicates that around 1 in 4 patients presenting to a
GP may be experiencing side effects from their medicines. This represents a major cause of morbidity and mortality.
However, awareness of side effects is generally limited to those printed in the product’s datasheet. Computer systems may have medicine side effect tables but these are also limited by what is provided in datasheets.
FAERS data is gathered over time resulting in identification of emergent side effects. Datasheet (SPC in UK and Europe, Drug labels in the US) listed side effects, mostly observed in clinical trials, represent about 15% of all observed potential side effects. In this respect, clinicians lack access to information that would help them identify potential problems. ADRx enables them to assess those side effects observed during widespread use.